Purpose
The influence of fasting blood glucose (FBG) and cholesterolemia primary liver cancer (PLC) in china was analyzed via a large prospective cohort study based on a community population, and the combined effects between them were investigated.
Materials and Methods
Overall, 98,936 staff from the Kailuan Group who participated in and finished physical examinations between 2006 and 2007 were included in the cohort study. Their medical information was collected and they were followed up after examination. The correlations of serum FBG or TC with PLC were analyzed. Then, we categorized all staff into four groups: normal FBG/ non-hypocholesterolemia, normal FBG/hypocholesterolemia, elevated FBG/non-hypocholesterolemia, elevated FBG/hypocholesterolemia and normal FBG/ non-hypocholesterolemia was used as a control group. The combined effects of elevated FBG and hypocholesterolemia with PLC were analyzed using the Age-scale Cox proportional hazard regression model.
Results
During 1,134,843.68 person*years follow up, a total of 388 PLC cases occured. We found the elevated FBG and hypocholesterolemia increases the risk for PLC, respectively. Compared with the non-hypocholesterolemia/normal FBG group, the risk of PLC was significantly increased in the non-hypocholesterolemia/elevated FBG group (HR=1.19,95%CI 0.88–1.62) and hypocholesterolemia/normal FBG group (HR=1.53,95%CI 1.19–1.97), and in the hypocholesterolemia/elevated FBG group (HR=3.16 95%CI2.13-4.69). And, a significant interaction effect was found of FBG and TC on PLC. All results were independent from the influence of liver disease.
Conclusion
Elevated serum FBG and hypocholesterolemia are risk factors for PLC, especially when combined. Thus, for the prevention and treatment of PLC, serum FBG and TC levels should be investigated.
Citations
Citations to this article as recorded by
The role of glucose-6-phosphatase activity in glucose homeostasis and its potential for diabetes therapy Lay Shuen Tan, Hwee Hui Lau, Essam M. Abdelalim, Chin Meng Khoo, Richard M. O’Brien, E. Shyong Tai, Adrian Kee Keong Teo Trends in Molecular Medicine.2025; 31(2): 152. CrossRef
Association between Metabolically Healthy Status and Risk of Gastrointestinal Cancer Haozhe Cui, Fei Tian, Yongliang Chen, Xiangming Ma Cancer Research and Treatment.2024; 56(1): 238. CrossRef
Identification of structural motifs critical for human G6PC2 function informed by sequence analysis and an AlphaFold2-predicted model Emily M. Hawes, Derek P. Claxton, James K. Oeser, Richard M. O’Brien Bioscience Reports.2024;[Epub] CrossRef
Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population Matthieu Wargny, Thomas Goronflot, Antoine Rimbert, Jérôme Boursier, Sofiane Kab, Joseph Henny, Antoine Lainé, Christophe Leux, Sarra Smati, Samy Hadjadj, Cédric Le May, Marcel Goldberg, Marie Zins, Bertrand Cariou Journal of Hepatology.2024; 80(6): 846. CrossRef
Biochemical and metabolic characterization of a G6PC2 inhibitor Emily M. Hawes, Mohsin Rahim, Zeinab Haratipour, Abigail R. Orun, Margaret L. O'Rourke, James K. Oeser, Kwangho Kim, Derek P. Claxton, Ray D. Blind, Jamey D. Young, Richard M. O'Brien Biochimie.2024; 222: 109. CrossRef
Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors Hao Li, Shuai Wang, Zhengqiang Yang, Xianwei Meng, Meng Niu Bioactive Materials.2024; 36: 376. CrossRef
Association between transitions in metabolic health and colorectal cancer across categories of body size phenotype: a prospective cohort study Qian Liu, Fei Si, Yuntao Wu, Jing Yu Obesity.2024; 32(10): 1948. CrossRef
Prognostic value of AFP-L3 and Des-γ-carboxy prothrombin in advanced primary liver cancer treated with Sorafenib and transarterial chemoembolization Shiwen Tang American Journal of Translational Research.2024; 16(9): 5004. CrossRef
Abdominal obesity, chronic inflammation and the risk of non-alcoholic fatty liver disease Dongna Zhao, Haozhe Cui, Zhiqiang Shao, Liying Cao Annals of Hepatology.2023; 28(4): 100726. CrossRef
Fasting plasma glucose and alanine aminotransferase on the risk of hepatocellular carcinoma: A nested case-control study Lizhen Zhang, Zhongge Wang, Ruirui Chen, Zhiyuan Cheng, Jingli Yang, Jing Li, Siyu Li, Yarong Chen, Lulu Xu, Yujia Hu, Yana Bai Cancer Epidemiology.2023; 84: 102362. CrossRef
Lipids, cholesterols, statins and liver cancer: a Mendelian randomization study Zicheng Liang, Zhen Zhang, Xiaoning Tan, Puhua Zeng Frontiers in Oncology.2023;[Epub] CrossRef
Triglyceride-glucose index associated with the risk of cardiovascular disease: the Kailuan study Qian Liu, Haozhe Cui, Yihan Ma, Xu Han, Zhiwei Cao, Yuntao Wu Endocrine.2022; 75(2): 392. CrossRef
Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study Haozhe Cui, Qian Liu, Yuntao Wu, Liying Cao Cardiovascular Diabetology.2022;[Epub] CrossRef
Association of triglyceride–glucose index and traditional risk factors with cardiovascular disease among non-diabetic population: a 10-year prospective cohort study Li Liu, Zhenguo Wu, Yifan Zhuang, Yerui Zhang, Huiliang Cui, Fanghong Lu, Jie Peng, Jianmin Yang Cardiovascular Diabetology.2022;[Epub] CrossRef
Purpose The occurrence pattern of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) in cancer treatment remains unclear.
Materials and Methods Phase II-III clinical trials that evaluated ICI-based treatments in cancer and were published between January 2007 and December 2019 were retrieved from public electronic databases. The pooled median time to onset (PMT-O), resolution (PMT-R), and immune-modulation resolution (PMT-IMR) of irAEs were generated using the metamedian package of R software.
Results Twenty-two eligible studies involving 23 clinical trials and 8,436 patients were included. The PMT-O of all-grade irAEs ranged from 2.2 to 14.8 weeks, with the longest in renal events. The PMT-O of grade ≥ 3 irAEs was significantly longer than that of all-grade irAEs induced by programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) inhibitors (27.5 weeks vs. 8.4 weeks, p < 0.001) and treatment of nivolumab (NIV) plus ipilimumab (IPI) (7.9 weeks vs. 6.0 weeks, p < 0.001). The PMT-R of all-grade irAEs ranged from 0.1 to 54.3 weeks, with the shortest and longest in hypersensitivity/infusion reaction and endocrine events, respectively. The PMT-IMR of grade ≥ 3 irAEs was significantly shorter than that of all-grade irAEs caused by PD-1/PD-L1 blockade (6.9 weeks vs. 40.6 weeks, p=0.002) and NIV+IPI treatment (3.1 weeks vs. 5.9 weeks, p=0.031).
Conclusion This study revealed the general and specific occurrence pattern of ICI-induced irAEs in pan-cancers, which was deemed to aid the comprehensive understanding, timely detection, and effective management of ICI-induced irAEs.
Citations
Citations to this article as recorded by
Oral and cutaneous immune‐related adverse events in cancer patients: Prevalence and overall survival Osias Vieira de Oliveira Filho, Ivana Lameiras Gibbons, Yuri de Lima Medeiros, Thiago Bueno de Oliveira, Nathaniel Simon Treister, Fabio Abreu Alves Oral Diseases.2025; 31(1): 278. CrossRef
Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system Naoto Okada, Tomoyuki Yanagi, Takaaki Sasaki, Miho Tamura, Masakazu Ozaki, Atsuyuki Saisyo, Takashi Kitahara International Journal of Cancer.2025; 156(2): 293. CrossRef
A Case of Olmesartan-associated Gastritis Observed Over Time Mizuho Fujisawa, Tetsuya Yoshizaki, Satoshi Urakami, Risa Ashizaki, Eri Nishikawa, Hiroshi Tanabe, Shinya Hoki, Ryosuke Ishida, Hitomi Hori, Chise Ueda, Hirofumi Abe, Madoka Takao, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama Internal Medicine.2025;[Epub] CrossRef
The use of peripheral blood biomarkers for predicting the risk of immune-related adverse events in immune checkpoint inhibitor therapy Louise E Duvall Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2025;[Epub] CrossRef
Developing alert thresholds and self-management advice for people receiving immune checkpoint inhibitors: a Multinational Association for Supportive Care in Cancer modified Delphi survey Julia Lai-Kwon, Claudia Rutherford, Stephanie Best, Hope S. Rugo, Christina H. Ruhlmann, Michael Jefford Supportive Care in Cancer.2025;[Epub] CrossRef
Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer Leila-Sophie Otten, Alessandra I. G. Buma, Berber Piet, Rob ter Heine, Michel M. van den Heuvel, Valesca P. Retèl PharmacoEconomics - Open.2025;[Epub] CrossRef
Clinical and economic impact of the advanced practice nurse in lung cancer patients receiving immunotherapy-based treatments: A quantitative study Jorgina Serra-López, Clara Pujol-Besora, Sergio Martínez-Recio, Andrés Barba Joaquín, Mariona Riudavets Melià, Ivana Sullivan, Jordi Torralbas-Ortega, Gina Lladó-Jordan, Margarita Majem, Maria-Antonia Martínez-Momblan European Journal of Oncology Nursing.2025; 74: 102809. CrossRef
Long-term immune related adverse events Leo Plaçais, Olivier Lambotte Current Opinion in Oncology.2025; 37(2): 142. CrossRef
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study Jonas Paul Wiegmann, Tabea Fröhlich, Nora Möhn, Laura Duzzi, Emily Narten, Johanna Aurich, Janin Thomas, Lea Grote‐Levi, Susann Mahjoub, Dominik Berliner, Thomas Wirth, Heiko Golpon, Benjamin‐Alexander Bollmann, Imke Von Wasilewski, Ralf Gutzmer, Florian Cancer Medicine.2025;[Epub] CrossRef
Application of Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma: Current Status, Challenges, and Future Directions Lingxiang Ran, Rui Zhao, Yu Li, Benfan Lin, Zhen Yang, Yuanyin Teng, Jingyi Li, Shi Wang, Hsu Yi Liang, Guangmo Hu AI Med.2025; 1(1): 1. CrossRef
Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients Ting Yan, Minghui Long, Chaoyi Liu, Jiwen Zhang, Xingyu Wei, Fei Li, Dehua Liao Frontiers in Pharmacology.2025;[Epub] CrossRef
Challenges and opportunities in single-domain antibody-based tumor immunotherapy Xiaozhi Xi, Shasha Guo, Yuchao Gu, Xuekai Wang, Qiang Wang Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2025; : 189284. CrossRef
Immune checkpoint inhibitor–related adverse events: Real-world experience from a single veterans’ affairs medical center Samantha Benz, Katherine A Sherman, Constantin A Dasanu, Juliana Alvarez-Argote Journal of Oncology Pharmacy Practice.2024; 30(4): 697. CrossRef
Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors Kremena Petrova Trichkova, Franziska Görtler, Line Bjørge, Cornelia Schuster Cancers.2024; 16(2): 250. CrossRef
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Gastroenterología y Hepatología.2024; 47(4): 401. CrossRef
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandí Revista Española de Enfermedades Digestivas.2024;[Epub] CrossRef
Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis Sangwon Shin, Jimin Moon, Chiyoon Oum, Seulki Kim, Soo Ick Cho, Yoojoo Lim, Chan-Young Ock, Seunghwan Shin BMC Cancer.2024;[Epub] CrossRef
A case of Stiff-person syndrome with muscle tonicity of the extremities and neck after use of Dulvalumab for lung adenocarcinoma Takashi Inoue, Kei Oiwa, Kazuhiro Horiuchi Rinsho Shinkeigaku.2024; 64(3): 176. CrossRef
Clinical and translational attributes of immune-related adverse events Karijn P. M. Suijkerbuijk, Mick J. M. van Eijs, Femke van Wijk, Alexander M. M. Eggermont Nature Cancer.2024; 5(4): 557. CrossRef
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach Desirèe Speranza, Mariacarmela Santarpia, Francesco Luppino, Fausto Omero, Enrica Maiorana, Mariacarmela Cavaleri, Elena Sapuppo, Vincenzo Cianci, Alessia Pugliese, Vito Racanelli, Giulia Maria Camerino, Carmelo Rodolico, Nicola Silvestris Expert Opinion on Drug Safety.2024; 23(11): 1405. CrossRef
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation Arielle Elkrief, Nicholas R. Waters, Natalie Smith, Angel Dai, John Slingerland, Nathan Aleynick, Binita Febles, Pooja Gogia, Nicholas D. Socci, Melissa Lumish, Paul A. Giardina, Jamie E. Chaft, Juliana Eng, Robert J. Motzer, Robin B. Mendelsohn, Kate A. Cancer Immunology Research.2024; 12(3): 308. CrossRef
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Gastroenterología y Hepatología (English Edition).2024; 47(4): 401. CrossRef
Pathogenesis, Diagnosis and Treatment of Immune-Related Cardiotoxicity 静宜 任 Advances in Clinical Medicine.2024; 14(03): 284. CrossRef
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients Alicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers, David Balakirouchenane, Jennifer Arrondeau, Pascaline Boudou-Rouquette, Marie-Claire Bretagne, Joe-Elie Salem, Xavier Declèves, Michel Vidal, Nora Kramkimel, Sarah Guegan, Selim Aractingi, Olivier Hui British Journal of Cancer.2024; 130(11): 1866. CrossRef
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian S Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, Romano Danesi, Stella D'Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida, Stefania Gori, Giampiero Marino, Rossella Mazzilli, Matteo Monami, Mon Cancer Treatment Reviews.2024; 126: 102734. CrossRef
Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms? Mohamed Mahmoud El-Sayed, Julia Raffaella Bianco, YiJing Li, Zsolt Fabian Cells.2024; 13(12): 1071. CrossRef
Mesenteric Panniculitis as a Side Effect of Nivolumab in a Patient with Larnyngeal Cancer O Karhan, Y Sezgin, S Ileri, S Tunc Nigerian Journal of Clinical Practice.2024; 27(6): 800. CrossRef
Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, T Cancer Medicine.2024;[Epub] CrossRef
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study Guihong Wan, Wenxin Chen, Sara Khattab, Katie Roster, Nga Nguyen, Boshen Yan, Ahmad Rajeh, Jayhyun Seo, Hannah Rashdan, Leyre Zubiri, Matthew J Hadfield, Shadmehr Demehri, Kun-Hsing Yu, William Lotter, Alexander Gusev, Nicole R LeBoeuf, Kerry L Reynolds, The Lancet Oncology.2024; 25(8): 1053. CrossRef
Selecting Immune Checkpoint Inhibitor Side Effects for Real-Time Monitoring in Routine Cancer Care: A Modified Delphi Study Julia Lai-Kwon, Michael Jefford, Stephanie Best, Iris Zhang, Claudia Rutherford JCO Oncology Practice.2024; 20(12): 1663. CrossRef
Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis Stephanie van der Leij, Karijn P.M. Suijkerbuijk, Medard F.M. van den Broek, Gerlof D. Valk, Jan Willem Dankbaar, Hanneke M. van Santen Frontiers in Endocrinology.2024;[Epub] CrossRef
Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action Antonio Malvaso, Pierpaolo Giglio, Luca Diamanti, Matteo Gastaldi, Elisa Vegezzi, Andrea Pace, Paola Bini, Enrico Marchioni Brain Sciences.2024; 14(8): 764. CrossRef
Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy Gerald J. Sun, Gustavo Arango-Argoty, Gary J. Doherty, Damian E. Bikiel, Dejan Pavlovic, Allen C. Chen, Ross A. Stewart, Zhongwu Lai, Etai Jacob iScience.2024; 27(9): 110634. CrossRef
Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite Instability-High Metastatic Colorectal Cancer Annie Xiao, Xiaochen Li, Chongkai Wang, Marwan Fakih Clinical Colorectal Cancer.2024;[Epub] CrossRef
Toxicity in the era of immune checkpoint inhibitor therapy Synat Keam, Naimah Turner, Fernanda G. Kugeratski, Rene Rico, Jocelynn Colunga-Minutti, Rayansh Poojary, Sayan Alekseev, Anisha B. Patel, Yuanteng Jeff Li, Ajay Sheshadri, Monica E. Loghin, Karin Woodman, Ashley E. Aaroe, Sarah Hamidi, Priyanka Chandrasek Frontiers in Immunology.2024;[Epub] CrossRef
Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors Christopher J. Hoimes, Suzanne McGettigan, Lee Schwartzberg The American Journal of Medicine.2024; 137(12): 1200. CrossRef
Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study Mari Yokoi, Atsushi Yonezawa, Daiki Hira, Tomohiro Handa, Kiminobu Tanizawa, Shunsaku Nakagawa, Masahiro Tsuda, Yasuaki Ikemi, Ryo Itotani, Hironori Yoshida, Motoo Nomura, Junichi Matsubara, Kosaku Murakami, Hiroaki Ozasa, Manabu Muto, Tomohiro Terada Journal of Pharmaceutical Health Care and Sciences.2024;[Epub] CrossRef
Melittin-incorporated nanomedicines for enhanced cancer immunotherapy Xuefeng Duan, Haoyang Zou, Jiazhen Yang, Shixian Liu, Tianmin Xu, Jianxun Ding Journal of Controlled Release.2024; 375: 285. CrossRef
Do corticosteroids affect immunotherapy efficacy in malignancy? – A systematic review Yoni Byron, Sonya Yegorova‐Lee, Martin Tio Cancer Medicine.2024;[Epub] CrossRef
Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver Luca Marzi, Andrea Mega, Chiara Turri, Stefano Gitto, Federica Ferro, Gilbert Spizzo International Journal of Molecular Sciences.2024; 25(21): 11676. CrossRef
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy Iris Teruel, Eva Castellà, Sabela Recalde, Gemma Viñas, Anna Petit, Macedonia Trigueros, Eva Martínez-Balibrea, Eudald Felip, Milana Bergamino, Adrià Bernat-Peguera, Beatriz Cirauqui, Vanesa Quiroga, Angelica Ferrando-Díez, Anna Pous, Assumpció López, Lai International Journal of Molecular Sciences.2024; 25(22): 12241. CrossRef
Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma Brooke Kielkowski, Diana Mansour, Brooke Ebbert, Kelsea Seago, Sijin Wen, Hang Li, Christine Barrett Journal of Oncology Pharmacy Practice.2024;[Epub] CrossRef
Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer Cynthia X. Wei, Sandra K. Althouse, Hirva Mamdani, Nasser H. Hanna, Greg A. Durm Clinical Lung Cancer.2024;[Epub] CrossRef
Safety of sequential immune checkpoint inhibitors after prior immune therapy Muhammad Awidi, Brendan Connell, Delaney Johnson, Isabel Craven, Rojer Ranjit, Brigitte Gil, Natalie Dal’Bo, Lewena Maher, Seanna Reilly Daves, Stephanie McDonald, Krishna S. Gunturu Journal of Cancer Research and Clinical Oncology.2023; 149(6): 2375. CrossRef
The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex Murielle N. Wahli, Stefanie Hayoz, Dennis Hoch, Christoph O. Ryser, Michèle Hoffmann, Amina Scherz, Birgit Schwacha-Eipper, Simon Häfliger, Julian Wampfler, Martin D. Berger, Urban Novak, Berna C. Özdemir Journal of Cancer Research and Clinical Oncology.2023; 149(7): 3847. CrossRef
Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy Atsushi Yamaguchi, Yoshitaka Saito, Katsuya Narumi, Ayako Furugen, Yoh Takekuma, Naofumi Shinagawa, Yasushi Shimizu, Hirotoshi Dosaka-Akita, Mitsuru Sugawara, Masaki Kobayashi Journal of Cancer Research and Clinical Oncology.2023; 149(4): 1659. CrossRef
Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large‐scale pharmacovigilance analysis Qian Guo, Jian Gao, Hui Guo, Jun Xie, Jingmin Cheng International Immunopharmacology.2023; 114: 109490. CrossRef
Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis Su Jeong Song, Yun-Kyoung Song, Mihwa Jang, Eunjeong Shin, Sung Yun Suh, Yoon Sook Cho, Ju-Yeun Lee, Jung Mi Oh Targeted Oncology.2023; 18(1): 147. CrossRef
Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis Qian Guo, Jin Ning Zhao, Ting Liu, Jian Gao, Hui Guo, Jing Min Cheng Frontiers in Pharmacology.2023;[Epub] CrossRef
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony S. K. Mok, Martin Reck, Gene G. Finley, Monika D. Kaul, Wei Yu, Nindhana Paranthaman, Ilze Bāra, Howard J. West JAMA Oncology.2023; 9(4): 527. CrossRef
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment Gaetano Maria Russo, Anna Russo, Fabrizio Urraro, Fabrizio Cioce, Luigi Gallo, Maria Paola Belfiore, Angelo Sangiovanni, Stefania Napolitano, Teresa Troiani, Pasquale Verolino, Antonello Sica, Gabriella Brancaccio, Giulia Briatico, Valerio Nardone, Alfons Diagnostics.2023; 13(4): 793. CrossRef
Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis Juyue Zhou, Zhonghai Du, Jie Fu, Xiuxiu Yi Frontiers in Immunology.2023;[Epub] CrossRef
Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report Nidhi Goel, Monica D. Levine, Laura M. Chambers, Christa I. Nagel Gynecologic Oncology Reports.2023; 47: 101174. CrossRef
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner Journal for ImmunoTherapy of Cancer.2023; 11(3): e006398. CrossRef
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients Berna C. Özdemir, Cristina Espinosa da Silva, Dimitri Arangalage, Pierre Monney, Sabina A. Guler, Uyen Huynh-Do, Guido Stirnimann, Lucia Possamai, Roman Trepp, Robert Hoepner, Anke Salmen, Camille L. Gerard, Petr Hruz, Lisa Christ, Sacha I. Rothschild Cancer Immunology, Immunotherapy.2023; 72(7): 1991. CrossRef
Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features Julianna Martel, Hannah L. Hanania, Anisha B. Patel Human Pathology.2023; 140: 144. CrossRef
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity Catherine C. Fahey, Thomas J. Gracie, Douglas B. Johnson Expert Review of Anticancer Therapy.2023; 23(7): 673. CrossRef
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment Rafael Morales-Barrera, Guillermo Villacampa, Natalia Vidal, Mariona Figols, Julia Giner, Teresa Bonfill, Cristina Suárez, Nely Díaz, Joaquín Mateo, Macarena González, Montserrat Domenech, Javier Puente, Joan Carles Clinical and Translational Oncology.2023; 25(12): 3556. CrossRef
The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review Julia Lai-Kwon, Jordan E. Cohen, Karolina Lisy, Claudia Rutherford, Afaf Girgis, Ethan Basch, Michael Jefford JCO Clinical Cancer Informatics.2023;[Epub] CrossRef
Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, Hiroki Kubota, Yusuke Noda, Maria Aoki, Yoshinobu Moritoki, Satoshi Nozaki, Satoshi Kurokawa, At International Journal of Urology.2023; 30(10): 866. CrossRef
Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy Shu-Jung Hsu, Yen-Cheng Chao, Xia-Hui Lin, Hua-Hua Liu, Yang Zhang, Wei-Feng Hong, Mao-Pei Chen, Xin Xu, Lan Zhang, Zheng-Gang Ren, Shi-Suo Du, Rong-Xin Chen Clinical and Experimental Immunology.2023; 212(3): 239. CrossRef
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, Tarek M. Meniawy, Michele Del Vecchio, Céleste Lebbé, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stéphane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen B Journal of Clinical Oncology.2023; 41(23): 3917. CrossRef
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between Hyo Sook Han, Praveen Vikas, Ricardo L.B. Costa, Nusrat Jahan, Ammanuel Taye, Erica M. Stringer-Reasor American Society of Clinical Oncology Educational Book.2023;[Epub] CrossRef
An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management Yiyu Cheng, Fangmei Ling, Junrong Li, Yidong Chen, Mingyang Xu, Shuang Li, Liangru Zhu Frontiers in Immunology.2023;[Epub] CrossRef
Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Tetsuya Tsuchida, Ai Yoshida, Takako Yamada, Akira Komoto The Journal of Dermatology.2023; 50(9): 1108. CrossRef
Real‐world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors Srilatha Dasari, William Tse, Jiasheng Wang British Journal of Haematology.2023; 202(6): 1205. CrossRef
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors André Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, Stellio Giacomini, Sébastien Bugeia, Garance Gutknecht, Gilliosa Spurrier-Bernard, Veronica Aedo-Lopez, Nuria Mederos, Sofiya Latifyan, Alfredo Addedo, Olivier Michielin, Manuela Eicher Supportive Care in Cancer.2023;[Epub] CrossRef
CD4 T cells and toxicity from immune checkpoint blockade Noah Earland, Wubing Zhang, Abul Usmani, Aishwarya Nene, Antonella Bacchiocchi, David Y. Chen, Mario Sznol, Ruth Halaban, Aadel A. Chaudhuri, Aaron M. Newman Immunological Reviews.2023; 318(1): 96. CrossRef
Anti‑PD1 therapy‑associated distal renal tubular acidosis: A case report Xuejia Qiu, Bingnan Ren, Lingzhi Fang, Zhanjun Dong Experimental and Therapeutic Medicine.2023;[Epub] CrossRef
Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review Minoru Kato, Junji Uchida International Journal of Urology.2023; 30(12): 1068. CrossRef
Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab Manuel A. Baarslag, Joosje H. Heimovaara, Jessica S.W. Borgers, Koen J. van Aerde, Hans J.P.M. Koenen, Ruben L. Smeets, Pauline L.M. Buitelaar, Dick Pluim, Shoko Vos, Stefanie S.V. Henriet, Jan Willem B. de Groot, Martine van Grotel, Hilde Rosing, Jos H. New England Journal of Medicine.2023; 389(19): 1790. CrossRef
Incidence and Timing of Immune-Related Adverse Events in Immune-Checkpoint Inhibitor-Treated Patients: A Retrospective Observational Study Kou Masaki, Motoyasu Miyazaki, Hideki Kakimoto, Yuma Fukiage, Haruka Fukue, Akio Nakashima, Osamu Imakyure Journal of Clinical Medicine.2023; 12(24): 7564. CrossRef
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview Priyatharcini Kejamurthy, K. T. Ramya Devi Medical Oncology.2023;[Epub] CrossRef
Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From theAJRSpecial Series on Imaging of Inflammation Sara Sheikhbahaei, Charles V. Marcus, Mohammad S. Sadaghiani, Steven P. Rowe, Martin G. Pomper, Lilja B. Solnes American Journal of Roentgenology.2022; 218(6): 940. CrossRef
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation Cody J. Peer, Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg, Mark J. Ratain The Journal of Clinical Pharmacology.2022; 62(4): 532. CrossRef
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah Earland, Matthew D. Vesely, Abul Usmani, Brandon E. Turner, Chloé B. Steen, Bogdan A. Luca, Ti Badri, Gunsagar S. Gulati, Milad R. Vahid, Farnaz Khameneh, Peter K. Harri Nature Medicine.2022; 28(2): 353. CrossRef
Guarantee‐time bias in studies on the relationship between immune‐related adverse events and antitumor activity Ka Man Cheung, Therese Yue Man Tsui, James Chung Hang Chow Cancer.2022; 128(13): 2549. CrossRef
CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma Kenichi Nishimura, Tatsuya Konishi, Toshiki Ochi, Ryuta Watanabe, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yuki Miyauchi, Tadahiko Kikugawa, Katsuto Takenaka, Takashi Saika Journal of Personalized Medicine.2022; 12(6): 888. CrossRef
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi Cancer Research and Treatment.2022; 54(4): 1005. CrossRef
Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences Ana Cardeña-Gutiérrez, Mónica López Barahona Frontiers in Medicine.2022;[Epub] CrossRef
Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy Afaf Abed, Ngie Law, Leslie Calapre, Johnny Lo, Vikas Bhat, Samantha Bowyer, Michael Millward, Elin S. Gray European Journal of Cancer.2022; 172: 98. CrossRef
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma Dirk Tomsitz, Max Schlaak, Sarah Zierold, Giulia Pesch, Thomas U. Schulz, Genoveva Müller, Christine Zecha, Lars E. French, Lucie Heinzerling Cancers.2022; 14(13): 3282. CrossRef
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer Ben-Max de Ruiter, Jons W. van Hattum, Djoeri Lipman, Theo M. de Reijke, R. Jeroen A. van Moorselaar, Erik J. van Gennep, A.H. Maartje Piet, Mila Donker, Tom van der Hulle, Jens Voortman, Jorg R. Oddens, Maarten C.C.M. Hulshof, Adriaan D. Bins European Urology.2022; 82(5): 518. CrossRef
Adverse Renal Effects of Anticancer Immunotherapy: A Review Maciej Borówka, Stanisław Łącki-Zynzeling, Michał Nicze, Sylwia Kozak, Jerzy Chudek Cancers.2022; 14(17): 4086. CrossRef
Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence Nari Kim, Eun Sung Lee, Sang Eun Won, Mihyun Yang, Amy Junghyun Lee, Youngbin Shin, Yousun Ko, Junhee Pyo, Hyo Jung Park, Kyung Won Kim Korean Journal of Radiology.2022; 23(11): 1089. CrossRef
Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data Jiasheng Wang, Srilatha Dasari, Dina Elantably, Akram Alkrekshi, Yeseong David Kim Acta Oncologica.2022; 61(9): 1157. CrossRef
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma Chan Kim, Hannah Yang, Ilhwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon JAMA Oncology.2022; 8(12): 1825. CrossRef
Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity Ik Shin Chin, Aman Khan, Anna Olsson-Brown, Sophie Papa, Gary Middleton, Claire Palles npj Genomic Medicine.2022;[Epub] CrossRef
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors Deniz Can Guven, Deniz Aral Ozbek, Taha Koray Sahin, Gozde Kavgaci, Melek Seren Aksun, Enes Erul, Hasan Cagri Yildirim, Elvin Chalabiyev, Cebrayil Cebroyilov, Tolga Yildirim, Omer Dizdar, Sercan Aksoy, Suayib Yalcin, Saadettin Kilickap, Mustafa Erman, Mus Anti-Cancer Drugs.2022;[Epub] CrossRef
Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer Lance L. Munn, Triantafyllos Stylianopoulos, Natalie K. Jain, C. Corey Hardin, Melin J. Khandekar, Rakesh K. Jain Clinical Cancer Research.2021; 27(10): 2706. CrossRef
Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma Jonathan T. Hunt, Laura M. Chambers, Meng Yao, Amy Joehlin-Price, Robert Debernardo, Peter G. Rose Gynecologic Oncology Reports.2021; 37: 100840. CrossRef
Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy Jie Zhang, Zhujiang Dai, Cheng Yan, Daorong Wang, Dong Tang Journal of Cancer Research and Clinical Oncology.2021; 147(12): 3639. CrossRef
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC Jay M. Lee, Anthony W. Kim, Tomasz Marjanski, Pierre-Emmanuel Falcoz, Masahiro Tsuboi, Yi-Long Wu, Shawn W. Sun, Barbara J. Gitlitz JTO Clinical and Research Reports.2021; 2(10): 100221. CrossRef
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Monalisa Ghosh, Ishmael Journal of Clinical Oncology.2021; 39(36): 4073. CrossRef
Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy Pan Shen, Xuan Deng, Zhishuo Hu, Zhe Chen, Yao Huang, Ke Wang, Kai Qin, Ying Huang, Xin Ba, Jiahui Yan, Liang Han, Shenghao Tu Frontiers in Medicine.2021;[Epub] CrossRef
Purpose
Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP (R-CHOP-14) could improve the outcome of the disease in Asian population.
Materials and Methods
Newly diagnosed DLBCL patients were centrally, randomly assigned (1:1) to receive R-CHOP- 14 or R-CHOP-21. R-CHOP-14 was administered every 2 weeks, and R-CHOP-21 was administered every 3 weeks. Primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), progression-free survival (PFS), response rate and toxicities.
Results
Seven hundred and two patients were randomly assigned to receive R-CHOP-14 (n=349) or R-CHOP-21 (n=353). With a median follow-up of 45.6 months, the two groups did not differ significantly in 3-year DFS (79.6% for R-CHOP-14 vs. 83.2% for R-CHOP-21, p=0.311), 3-year OS (77.5% for R-CHOP-14 vs. 77.6% for R-CHOP-21, p=0.903), or 3-year PFS (63.2% for R-CHOP-14 vs. 66.1% for R-CHOP-21, p=0.447). Patients with an International Prognostic Index (IPI) score ≥ 2 had a poorer prognosis compared to those with an IPI score < 2. Grade 3/4 hematologic and non-hematologic toxicities were manageable and similar between R-CHOP-14 and R-CHOP-21.
Conclusion
R-CHOP-14 did not improve the outcome of DLBCL compared to R-CHOP-21 in Asian population. With manageable and similar toxicities, both of the two regimens were suitable for Asian DLBCL patients. For high-risk patients with IPI ≥ 2, new combination regimens based on R-CHOP deserve further investigation to improve efficacy.
Citations
Citations to this article as recorded by
Prediction of 5‐year overall survival of diffuse large B‐cell lymphoma on the pola‐R‐CHP regimen based on 2‐year event‐free survival and progression‐free survival Wan‐Ru Zhang, Xin Liu, Qiu‐Zi Zhong, Tao Wu, Yong Yang, Bo Chen, Hao Jing, Yuan Tang, Jing Jin, Yue‐Ping Liu, Yong‐Wen Song, Hui Fang, Ning‐Ning Lu, Ning Li, Yi‐Rui Zhai, Wen‐Wen Zhang, Shu‐Lian Wang, Fan Chen, Lin Yin, Shu‐Nan Qi, Ye‐Xiong Li Cancer Medicine.2024;[Epub] CrossRef
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study Yan Qin, Yongping Song, Dong Wang, Ou Bai, Jifeng Feng, Xiuhua Sun, Lihua Qiu, Jianmin Yang, Yu Yang, Zhao Wang, Jianda Hu, Huaqing Wang, Hang Su, Zhengming Jin, Wenbin Qian, Chuan Jin, Mingzhi Zhang, Ding Yu, Li Liu, Guoan Chen, Yarong Li, Tao Sun, Jie J BMC Cancer.2024;[Epub] CrossRef
Palmitic acid reduces the methylation of the FOXO1 promoter to suppress the development of diffuse large B-cell lymphoma via modulating the miR-429/DNMT3A axis Weiming LI, Ming GAO, Weili XUE, Xiaoli LI, Yu CHANG, Kaixin ZHANG, Chenyu WEN, Mingzhi ZHANG Chinese Journal of Natural Medicines.2024; 22(6): 554. CrossRef
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving S Yu Ri Kim, Jin Seok Kim, Won Seog Kim, Hyeon Seok Eom, Deok-Hwan Yang, Sung Hwa Bae, Hyo Jung Kim, Jae Hoon Lee, Suk-Joong Oh, Sung-Soo Yoon, Jae-Yong Kwak, Chul Won Choi, Min Kyoung Kim, Sung Young Oh, Hye Jin Kang, Seung Hyun Nam, Hyeok Shim, Joon Seong Cancer Research and Treatment.2023; 55(4): 1355. CrossRef
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study Lorenz Thurner, Marita Ziepert, Christian Berdel, Christian Schmidt, Peter Borchmann, Dominic Kaddu-Mulindwa, Andreas Viardot, Mathias Witzens-Harig, Judith Dierlamm, Mathias Haenel, Bernd Metzner, Gerald Wulf, Eva Lengfelder, Ulrich B. Keller, Norbert Fr HemaSphere.2023; 7(7): e904. CrossRef
Treatment of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Literature Review and Meta-Analysis Aleksander Sergeevich Luchinin Clinical oncohematology.2022; 15(2): 130. CrossRef
The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients Shunfeng Hu, Na Chen, Kang Lu, Changqing Zhen, Xiaohui Sui, Xiaosheng Fang, Ying Li, Yingshu Luo, Xiangxiang Zhou, Xin Wang Leukemia & Lymphoma.2021; 62(6): 1335. CrossRef
Primary diffuse large B-cell lymphoma of the fallopian tube treated with a combination of surgery and chemotherapy Ye Zhou, Chao Zhang, Yingying Gong, Linqing Yang, Yunfei Wang Medicine.2021; 100(3): e24049. CrossRef
Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy Anuvrat Sircar, Sayan Chowdhury, Amber Hart, William Bell, Satishkumar Singh, Lalit Sehgal, Narendranath Epperla International Journal of Molecular Sciences.2020; 21(3): 904. CrossRef
Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review Jie Zhu, Yong Yang, Jin Tao, Shu-Lian Wang, Bo Chen, Jian-Rong Dai, Chen Hu, Shu-Nan Qi, Ye-Xiong Li Leukemia.2020; 34(10): 2576. CrossRef
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma Murali Kesavan, Toby A. Eyre, Graham P. Collins Current Hematologic Malignancy Reports.2019; 14(4): 207. CrossRef
Immunohistochemical Subtype and Parameters of International Prognostic Index in the New Prognostic Model of Diffuse Large B-Cell Lymphoma Svetlana Valer'evna Samarina, A.S. Luchinin, N.V. Minaeva, I.V. Paramonov, D.A. D'yakonov, E.V. Vaneeva, V.A. Rosin, S.V. Gritsaev Clinical oncohematology.2019; 12(4): 25. CrossRef
Purpose
Previous studies reported an association between an increased risk of tongue cancer and radiation treatment for nasopharyngeal carcinoma (NPC). This study compared the clinicopathologic characteristics and outcomes of tongue squamous cell carcinoma (TSCC) in patients with and without a history of radiotherapy for NPC.
Materials and Methods
From 1965 to 2009, a total of 73 patients were diagnosed with TSCC with a history of radiotherapy for NPC. The patients were matched in a 1:3 ratio with patients with sporadic TSCC according to age, sex, and year of the TSCC diagnosis. The primary endpoint was the overall survival.
Results
The median interval from NPC to TSCC was 82 months. The NPC survivors were more likely to be diagnosed with a more advanced T classification, less likely to have lymph node involvement, and more likely to have the tumor located in the dorsum of the tongue than sporadic TSCC. Regarding the histologic characteristics, the NPC survivors were more likely to have a weak lymphocytic host response, low tumor budding, and low risk of a worse pattern of invasion. The sporadic TSCC patients had a better overall survival (hazard ratio, 0.690; p=0.033) than the NPC survivors. In competing risks analysis, the cumulative incidence functions for the competing event (documented non-tongue cancer death) were significantly higher in the NPC survivors (Gray’s test, p=0.001).
Conclusion
TSCC patients with a history of radiotherapy for NPC appear to have particular clinicopathologic features, a poorer survival, and are more likely to die from non-tongue cancer causes than those with sporadic TSCC.
Citations
Citations to this article as recorded by
Radiotherapy upregulated immune checkpoints contribute to the development of second primary OSCC Li Wang, Siyu Wang, Jiayu Zhang, Jianmin Peng, Bin Cheng, Huan Li, Qinchao Hu Oral Diseases.2024; 30(4): 2188. CrossRef
Impact of histopathological parameters in prognosis of oral squamous cell carcinoma R. P. Ekanayaka, W. M. Tilakaratne Oral Diseases.2024;[Epub] CrossRef
Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma James C. H. Chow, Wah Cheuk, William C. S. Cho, Chi-Fai Wong, Dennis W. Y. Au, Anthony H. P. Tam, Rachel C. W. Wong, Jeffrey C. H. Chan, Simon C. C. Law, Roger K. C. Ngan, Kam-Hung Wong, Ka-Man Cheung JAMA Network Open.2023; 6(7): e2323890. CrossRef
Clinical characterization of radiation-associated muscle-invasive bladder cancer Sybil T. Sha, Edward Christopher Dee, Matthew Mossanen, Brandon A. Mahal, Cierra Zaslowe-Dude, Trevor J. Royce, Michelle S. Hirsch, Guru Sonpavde, Mark A. Preston, Paul L. Nguyen, Kent W. Mouw, Vinayak Muralidhar Urology.2021; 154: 208. CrossRef
SPP1 and FN1 are significant gene biomarkers of tongue squamous cell carcinoma Xiao-Liang Xu, Hui Liu, Ying Zhang, Su-Xin Zhang, Zhong Chen, Yang Bao, Tian-Ke Li Oncology Letters.2021;[Epub] CrossRef
Secondary Squamous Cell Carcinoma of the Oral Cavity after Nasopharyngeal Carcinoma Liyuan Dai, Qigen Fang, Peng Li, Junfu Wu, Xu Zhang Cancer Research and Treatment.2020; 52(1): 109. CrossRef
Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG James C.H. Chow, Anthony H.P. Tam, Ka-Man Cheung, Victor H.F. Lee, Chi-Leung Chiang, Macy Tong, Edwin C.Y. Wong, Alice K.W. Cheung, Sunny P.C. Chan, Jessica W.Y. Lai, Roger K.C. Ngan, Wai-Tong Ng, Anne W.M. Lee, Kwok-Hung Au Oral Oncology.2020; 111: 105012. CrossRef
BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma Miao Wang, Lu Zhao, Dongdong Tong, Linrui Yang, Hongjie Zhu, Qing Li, Fenghe Zhang International Immunopharmacology.2019; 76: 105921. CrossRef
Surgical treatment of early tongue squamous cell carcinoma and patient survival Lansheng Zhu, Yanling Wang, Rui Li, Aiqun Liu, Xiaoping Zhang, Chunran Zuo, Xiaoting Xu Oncology Letters.2019;[Epub] CrossRef
Keratin 6A gene silencing suppresses cell invasion and metastasis of nasopharyngeal carcinoma via the β‑catenin cascade Chuanjun Chen, Huiguo Shan Molecular Medicine Reports.2019;[Epub] CrossRef
Tumour budding in oral squamous cell carcinoma: a meta-analysis Alhadi Almangush, Matti Pirinen, Ilkka Heikkinen, Antti A Mäkitie, Tuula Salo, Ilmo Leivo British Journal of Cancer.2018; 118(4): 577. CrossRef
The poor outcome of second primary oral squamous cell carcinoma is attributed to Bmi1 upregulation Qinchao Hu, Tong Wu, Xiaobing Chen, Huan Li, Zhicheng Du, Yuantao Hao, Jianmin Peng, Shanshan Tai, Ming Song, Bin Cheng Cancer Medicine.2018; 7(4): 1056. CrossRef
Clinical analysis of second primary gingival squamous cell carcinoma after radiotherapy Xiaoyan Fu, Shuwei Chen, Weichao Chen, Zhongyuan Yang, Ming Song, Hao Li, Huayong Zhang, Fan Yao, Xuan Su, Tianrun Liu, An-Kui Yang Oral Oncology.2018; 84: 20. CrossRef